Clinical trial
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in…
NCT00384215 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00384215 |
|---|---|
| Title | Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin |
| Official title | Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | insulin glargine [rDNA origin] injection |
| Enrollment | 352 |
| Start date | Dec 1, 2001 |
| Completion | Feb 1, 2005 |
| First posted | Oct 6, 2006 |
| Last update posted | Jan 11, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: